Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call

SAN DIEGO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( www.apricusbio.com) announced today that it will hold a conference call to discuss its first quarter 2013 financial results and recent corporate highlights on Friday, May 10, 2013 at 9:00 a.m. ET. The Company expects to file its Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on Friday, May 10, 2013.

The call can be accessed in the U.S. by dialing 877-407-9210 and outside of the U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus Bio Conference Call. The conference call will also be webcast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=170957 . The teleconference replay will be available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay Passcode 413843 is required for playback. The webcast replay will be available for three months.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories, and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one approximately 400-patient Phase III study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com.  You can also receive information at http://twitter.com/apricusbio .
CONTACT: Apricus Bio Investor Relations:                  David Pitts or Lourdes Catala         Argot Partners         212-600-1902         david@argotpartners.com         lourdes@argotpartners.com

Apricus logo

If you liked this article you might like

Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement

3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More

4 Stocks Under $10 in Breakout Territory

Biotech Stock Mailbag: Apricus, Avanir

5 Stocks Poised for Breakouts